Corning Jiekui Pharmaceutical-B (09966): Phase I/II clinical study results of JSKN033 in treating CC patients who failed standard therapy were presented as a rapid oral presentation at the 2026 ESMO Congress

Zhitong Finance APP News, Alphamab Oncology-B (09966) announced that the clinical study results of JSKN033 (a high-concentration subcutaneous injection combination formulation composed of a HER2 bispecific ADC and a PD-L1 immune checkpoint inhibitor) in the treatment of CC patients who failed standard therapy in a Phase I/II clinical study in China (Study No.: JSKN033-102) were presented in a rapid oral presentation at the 2026 ESMO Congress.